Navigation Links
Nektar Therapeutics Reports Financial Results for the Second Quarter of 2013
Date:8/8/2013

SAN FRANCISCO, Aug. 8, 2013 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the second quarter ended June 30, 2013.

Cash and investments in marketable securities at June 30, 2013 were $226.9 million.

"I am very pleased with Nektar's performance this year," said Howard W. Robin, President and Chief Executive Officer of Nektar. "AstraZeneca has confirmed that they will be filing both the naloxegol NDA and MAA in September.  Naloxegol could be the first once-daily oral medication to treat patients with opioid-induced constipation.  In June, we announced positive data from our Human Abuse Liability study for NKTR-181, our wholly-owned analgesic molecule which has received Fast Track Status from the FDA.  The results clearly demonstrated that drug abusers could not discriminate NKTR-181 from placebo at doses that we know produced analgesia in earlier studies.  We are on track to report high-level results from the Phase 2 efficacy study of NKTR-181 in chronic pain patients this summer.  Finally, we recently completed enrollment in our Phase 3 study of NKTR-102 ahead of schedule.  NKTR-102 is the first long-acting topoisomerase I inhibitor being developed for the treatment of advanced breast cancer and we expect survival data from this pivotal trial next year."

Revenue in the second quarter of 2013 was $33.9 million as compared to $23.7 million in the second quarter of 2012. Year-to-date revenue for 2013 was $56.9 million as compared to $41.6 million in the first half of 2012.  Revenues included non-cash royalty revenue, related to our February 2012 royalty monetization, of $3.8 million and $8.2 million in the second quarter and first half of 2013, respectively, and $3.5 million in both the second quarter and first half of 2012. This non-cash royalty revenue is offset by non-cash inter
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
3. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
4. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
5. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
6. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
7. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
8. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
9. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
10. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
11. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)...  Regulatory leaders in the pharmaceutical industry continue to ... "21 st Century Cures." This ... by Congress soon and if enacted into law, it ... developed and marketed in the United States ... to consider how the proposed changes could impact their ...
(Date:4/17/2015)... -- Nonin Medical, a global leader in noninvasive medical ... Steve Bucholz will retire May 1. Company ... as Chief Executive Officer. In addition, Mr. Isaacson will ... will transition to David Noel , Chief Financial ... instrumental to Nonin Medical,s growth," Mr. Isaacson said. "Under ...
(Date:4/17/2015)... , Apr. 17, 2015 Research and Markets ... of the "Medical Equipment Rental and Leasing - ... This report analyzes the worldwide markets for ... report provides separate comprehensive analytics for the US, ... and Rest of World. Annual estimates and ...
Breaking Medicine Technology:21st Century Cures: A Regulatory Game-Changer for the Pharmaceutical Industry 2Nonin Medical's Philip Isaacson Expands CEO Role; President and COO Steve Bucholz to Retire May 1 2Medical Equipment Rental and Leasing Market 2015-2020 - Global Strategic Business Report - Healthcare Spending Slowdown Bodes Well for Medical Equipment Leasing 2
... (Amex: SYI ) today announced findings from ... can,determine a person,s haptoglobin pheno/genotype in less than ... risk in patients with,diabetes. The study was presented ... Symposium in Bethesda, Maryland., "This study shows ...
... Texas, Sept. 10 The first-ever human,clinical trial ... was,recently conducted, testing whether the tea can possibly ... trial also generated the first human safety data ... consumption of rooibos tea is safe for the ...
Cached Medicine Technology:Data Confirm Synvista Therapeutics Haptoglobin Diagnostic Test Kit Success in Rapidly Determining Cardiovascular Risk in Patients with Diabetes 2Data Confirm Synvista Therapeutics Haptoglobin Diagnostic Test Kit Success in Rapidly Determining Cardiovascular Risk in Patients with Diabetes 3Data Confirm Synvista Therapeutics Haptoglobin Diagnostic Test Kit Success in Rapidly Determining Cardiovascular Risk in Patients with Diabetes 4Clinical Trial Shows Cardiovascular Benefits of Rooibos, Popular Antioxidant Herbal Tea from South Africa 2Clinical Trial Shows Cardiovascular Benefits of Rooibos, Popular Antioxidant Herbal Tea from South Africa 3Clinical Trial Shows Cardiovascular Benefits of Rooibos, Popular Antioxidant Herbal Tea from South Africa 4Clinical Trial Shows Cardiovascular Benefits of Rooibos, Popular Antioxidant Herbal Tea from South Africa 5
(Date:4/19/2015)... HealthPostures, LLC , a leading American ... it’s pioneering ergonomics products at the Wisconsin Safety and ... Professional Development Conference and Expo . The products, the ... in volume by call centers, educational organizations, retailers, government ... to a desk, the TaskMate Go 6350 and the ...
(Date:4/18/2015)... April 18, 2015 Carinsurancesavings.biz has released ... plans are cheaper during Spring. , Spring ... insurance plan. Drivers should make sure they compare the ... vehicles. Clients can learn more about Spring car insurance ... , Auto insurance quotes are becoming more and more ...
(Date:4/18/2015)... April 18, 2015 Insuranceautoquote.info has released ... online auto insurance quotes . , Clients can ... single website. The online environment provides important advantages for ... , Drivers who do not have coverage for ... during any season, day or hour. Many agencies offer ...
(Date:4/18/2015)... 2015 In the past few weeks, ... changes. , "We had to run maintenance on our ... said Jennifer Ramirez, the PR Director. "It disrupted our ... that we are back on track after having completed ... of changing phone systems which has not allowed some ...
(Date:4/18/2015)... 2015 PHOENIX, ARIZONA – In March, ... 11 other secure destruction professionals across the United States, ... He will now display “CSDS” as a professional title ... the National Association of Information Destruction 2015 Annual Conference ... Texas. Of the 20 people who took the exam, ...
Breaking Medicine News(10 mins):Health News:HealthPostures' TaskMate Products to be Exhibited at the Wisconsin and Iowa-Illinois Safety Conferences 2Health News:Auto Insurance Plans Are Cheaper During Spring! 2Health News:Clients Can Review Car Insurance Quotes Online To Find Low Cost Offers! 2Health News:TheBeautyPlace.com Temporary Number Available 2
... 50 Percent have Missing Teeth and Few Understand the ... vs. Other Physical FeaturesSAN DIEGO, Feb. 26 ... the largest known consumer survey in dentistry at the ... of Osseointegration . The survey, which evaluated the responses ...
... and CINCINNATI, Feb. 26, 2009 Reliance,Products LP and ... that the U.S.,Environmental Protection Agency (EPA) has approved new ... removal of arsenic, the parasites,Cryptosporidium and Giardia, and cause-marketing ... ) , The EPA has ...
... Pharmaceuticals (Nasdaq: ENDP ) announced today the ... of directors. Mr. Montague, 62, who was chief ... retired in July last year. Mark IV is ... for the transportation, industrial and automotive markets. He joined ...
... stress, more peace after sessions, study finds , , THURSDAY, ... emotional health of breast cancer patients, contends a new ... and distress that many women with breast cancer experience, ... in the midst of breast cancer is a significant ...
... WORTH, Texas, Feb. 26 Coria Laboratories,the newly ... VRX ), today announced six data presentations ... the American Academy of Dermatology (AAD),taking place March ... San Francisco. The,presentations demonstrate the efficacy and ...
... Calif., Feb. 26 If you,re looking for an ... Relief Program, consider Wells Fargo Bank, which has received ... Francisco-based bank has inexplicably withheld tens of thousands of ... a Southern California behavioral healthcare treatment center have used ...
Cached Medicine News:Health News:Nobel Biocare Unveils Results of the Largest U.S. Consumer Dental Survey 2Health News:Nobel Biocare Unveils Results of the Largest U.S. Consumer Dental Survey 3Health News:Nobel Biocare Unveils Results of the Largest U.S. Consumer Dental Survey 4Health News:Reliance Products and Procter & Gamble Announce EPA Approval of New Claims for PUR Purifier of Water 2Health News:Reliance Products and Procter & Gamble Announce EPA Approval of New Claims for PUR Purifier of Water 3Health News:Endo Pharmaceuticals Appoints William Montague to Board of Directors 2Health News:Endo Pharmaceuticals Appoints William Montague to Board of Directors 3Health News:Yoga May Bring Calm to Breast Cancer Treatment 2Health News:Coria Laboratories Announces Acanya(TM) Gel Data Presentations at 67th American Academy of Dermatology Annual Meeting 2Health News:Coria Laboratories Announces Acanya(TM) Gel Data Presentations at 67th American Academy of Dermatology Annual Meeting 3Health News:Coria Laboratories Announces Acanya(TM) Gel Data Presentations at 67th American Academy of Dermatology Annual Meeting 4Health News:Coria Laboratories Announces Acanya(TM) Gel Data Presentations at 67th American Academy of Dermatology Annual Meeting 5Health News:According to A Better Tomorrow Wells Fargo's Credit Card Processing Division is Withholding Tens of Thousands of Dollars Owed to a Southern California-Based Behavioral Healthcare Treatment Center 2Health News:According to A Better Tomorrow Wells Fargo's Credit Card Processing Division is Withholding Tens of Thousands of Dollars Owed to a Southern California-Based Behavioral Healthcare Treatment Center 3
Malaria Pf/Pv Assay Range...
Malaria Pf. Assay Range...
An immunochromatographic test for detection of 4 species of Plasmodium antigen ( P. falciparum , P. vivax , P. malariae , P. ovale ) in whole blood....
192 Test HRP-II Enzyme Immunoassay for the presence of Plasmodium falciparum infection....
Medicine Products: